The impact of parathyroid hormone replacement with palopegteriparatide on synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism.
Palopegteriparatide may help maintain normal levels of 1,25-dihydroxy vitamin D in patients with hypoparathyroidism over a period of 3.5 years.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
The study investigates the effect of palopegteriparatide on the synthesis of 1,25-dihydroxy vitamin D in patients with hypoparathyroidism. It reports that 25(OH)D and 1,25(OH)2D levels were maintained within normal limits over a duration of 3.5 years. No specific numeric findings are detailed in the abstract.
Abstract
<h4>Introduction</h4>Parathyroid hormone (PTH) is the primary regulator of calcium and phosphate balance via direct action on the kidneys and bones and indirect action on the intestine. Hypoparathyroidism is caused by insufficient levels of PTH, leading to 1,25-dihydroxy vitamin D (1,25[OH]<sub>2</sub>D) deficiency. PTH-induced 1,25(OH)<sub>2</sub>D production is a highly regulated process essential for physiological functions that is reduced or absent in hypoparathyroidism.<h4>Areas covered</h4>Physiological synthesis of 1,25(OH)<sub>2</sub>D requires 25-hydroxy vitamin D (25[OH]D) 1-α-hydroxylation via the renal CYP27B1 enzyme. Enzyme activity is dependent on CYP27B1 transcription, which is induced by specific PTH-1 receptor (PTH1R) activation that results in endosomal-derived intracellular cyclic adenosine monophosphate formation. Palopegteriparatide, a prodrug of PTH(1-34) used as replacement therapy in hypoparathyroidism, is designed to provide active PTH that exerts its physiological effect through the same affinity and binding to receptors as endogenous PTH. Throughout 3.5 years in the phase 3 PaTHway trial, 25(OH)D and 1,25(OH)<sub>2</sub>D levels were maintained within normal limits as a result of restoring endogenous production of 1,25(OH)<sub>2</sub>D and physiological signaling with palopegteriparatide treatment, thereby facilitating independence from active vitamin D.<h4>Expert opinion</h4>1,25(OH)<sub>2</sub>D production can be compromised by even small changes to PTH that bias the physiological interaction between PTH and PTH1R. Thus, ensuring formation of 1,25(OH)<sub>2</sub>D should be a key outcome of interest in drug development of PTH replacement therapies. Data from clinical trials demonstrate active PTH released from palopegteriparatide interacts with PTH1R to ensure adequate 1,25(OH)<sub>2</sub>D synthesis, enabling independence from active vitamin D analogues, and confirms its position as a PTH replacement therapy.
Background
This paper addresses the role of parathyroid hormone (PTH) in regulating calcium and phosphate balance, particularly in the context of hypoparathyroidism, where insufficient PTH leads to deficiencies in 1,25-dihydroxy vitamin D. Prior knowledge indicates that PTH is crucial for the synthesis of 1,25(OH)2D through its action on the kidneys. This study is significant as it explores the potential of palopegteriparatide, a PTH replacement therapy, to restore normal vitamin D levels in affected individuals.
Methods
The study is based on data from the phase 3 PaTHway trial, focusing on the effects of palopegteriparatide on vitamin D synthesis over a period of 3.5 years. Specific details regarding the population, sample size, dosing regimen, and primary versus secondary outcomes are not reported in the abstract.
Results
Not reported in abstract.
Interpretation
The findings suggest that palopegteriparatide may effectively restore 1,25(OH)2D levels in patients with hypoparathyroidism, but without specific numeric data, it is difficult to assess the clinical significance of these results. The lack of detailed outcomes limits the ability to compare these findings with existing literature on PTH replacement therapies. Potential confounds include the absence of detailed methodology and sample size, which may affect the robustness of the conclusions.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- No specific numeric data provided.
- Details on sample size and dosing regimen not available.